IFRX$1.59
$1.62
Chart
Performance
Key Stats
AI IFRX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralInflaRx N.V. shows potential in its clinical pipeline but faces significant financial challenges and an uncertain market outlook. A cautious approach is warranted.
Thematic
The company operates in the biopharmaceutical sector, focusing on inflammatory and autoimmune diseases, a field with ongoing innovation and unmet medical needs. The use of C5a technology presents a unique approach.
Fundamental
The company's financials indicate a significant burn rate and lack of profitability, typical for clinical-stage biotechs. However, cash reserves are substantial, providing runway.
Technical
The stock price has experienced significant volatility, with recent price action showing some recovery but still trading well below its 52-week high. Technical indicators are mixed.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 75 |
| Rare and Chronic Diseases Focus | 80 |
| Technology Platform (C5a) | 70 |
| Partnerships and Collaborations | 65 |
| Market Adoption & Reimbursement | 50 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Revenue Growth | 10 |
| Balance Sheet Health | 95 |
| Cash Flow | 15 |
| Earnings Consistency | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume | 60 |
| Moving Averages | 45 |
| Short-term Performance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improved EPS Surprise
InflaRx N.V. has demonstrated positive EPS surprises in recent quarters (e.g., +29.35% in Q2 2025, +68.0% in Q1 2025), indicating better-than-expected earnings generation.
Increasing Cash Position
Cash and cash equivalents have shown an increasing trend, growing from $12.77 million in Q4 2023 to $18.38 million in Q4 2024, providing operational flexibility.
Bearish Points (8)
Significant Net Losses
InflaRx N.V. has consistently reported substantial net losses, with net income at -$46.06 million in 2024, indicating ongoing profitability challenges and a need for significant future revenue.
Minimal Revenue
Revenue generation is extremely low (e.g., $165,789 in 2024), indicating that the company is heavily reliant on its pipeline and has not yet established significant commercial sales.
Calendar
August 2025
6
Next Earnings Date
H: $-0.19
A: $-0.20
L: $-0.21
H: 59.00K
A: 21.80K
0Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Seasonals
Price Target
3.75 USD
The 39 analysts offering 1 year price forecasts for IFRX have a max estimate of 10.36 and a min estimate of 2.07.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Acquired Alexion Pharmaceuticals, a pioneer and market leader in complement inhibition (e.g., Soliris, Ultomiris), directly addressing the C5/complement pathway which is InflaRx's core focus. This makes them a direct competitor or benchmark in the complement space.
Weight: 90
Clinical-stage company with marketed drugs (e.g., SYFOVRE) and pipeline programs focused on complement inhibition (specifically C3), a key pathway for inflammatory and autoimmune diseases. This creates direct therapeutic and mechanistic overlap with IFRX.
Weight: 88
Clinical-stage biopharmaceutical company focused on inflammatory and autoimmune diseases. They have marketed products (Arcalyst) for certain inflammatory conditions and explore various immune pathways, indicating a direct therapeutic area and potential mechanistic overlap.
Weight: 85
Biopharmaceutical company focused on autoimmune diseases, specifically lupus nephritis (with marketed drug Lupkynis), a severe inflammatory kidney condition. This represents a direct overlap in the therapeutic area of autoimmune/inflammatory diseases.